Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor, and markers of immune activation in HIV-infected subjects receiving interleukin 2

AIDS Research and Human Retroviruses

Volumn 18, Issue 9, 2002, Pages 661-665

  Sha, Beverly E ^a   Valdez, Hernan ^b   Gelman, Rebecca S ^c   Landay, Alan L ^a   Agosti, Jan ^d   Mitsuyasu, Ronald ^e   Pollard, Richard B ^f   Mildvan, Donna ^g   Namkung, Ann ^h   Ogata Arakaki, Debra M ⁱ   Fox, Lawrence ^j   Estep, Scharla ^j   Erice, Alejo ^k   Kilgo, Patrick ^c   Walker, Robert E ^j,l   Bancroft, Lynne ^m   Lederman, Michael M ^b  

^a RUSH MEDICAL COLLEGE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d AMGEN INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g BETH ISRAEL MEDICAL CENTER   (United States)

^h AIDS Clinical Trials Group Operations Center   (United States)

ⁱ UNIVERSITY OF HAWAII   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^l MEDIMMUNE   (United States)

^m FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; DRUG UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TEMPERATURE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL RESPONSE MODIFIERS; C-REACTIVE PROTEIN; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2; INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036434120     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202760019365     Document Type: Article

References (15)

1. Bazzoni F and Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-1725.
2. Matsuyama T, Kobayashi N, and Yamamoto N: Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease? AIDS 1991;5:1405-1417.
3. Poli G and Fauci AS: Cytokine modulation of HIV expression. Semin Immunol 1993;5:165-173.
4. α therapy in rheumatoid arthritis. J Immunol 1999;163:1521-1528.
5. Moreland LW, Schiff MH, Baumgartner SW, et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-486.
6. Kinter AI, Poli G, Fox L, Hardy E, and Fauci AS: HIV replication in IL-2 stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995;154:2448-2459.
7. Brouckaert P, Spriggs DR, Demetri G, Kufe DW, and Fiers W: Circulating interleukin-6 during a continuous infusion of tumor necrosis factor and interferon γ. J Exp Med 1989;169:2257-2262.
8. α by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 1996;174:63-68.
9. Bataille R and Klein B: C-reactive protein levels as a direct indicator of interleukin-6 levels in human in vivo. Arthritis Rheum 1992;35:982-984.
10. Eskandari MK, Nguyen DT, Kunkel SL, and Remick DG: WEHI 164 subclone 13 assay for TNF: Sensitivity, specificity, and reliability. Immunol Invest 1990;19:69-79.
11. Zack Howard OM, Clouse KA, Smith C, Goodwin RG, and Farrar WL: Soluble tumor necrosis factor receptor; inhibition of human immunodeficiency virus activation. Proc Natl Acad Sci USA 1993;90:2335-2339.
12. + patients. In: 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 4-8, 2000 (Abstract 348).
13. Aboulafia DM, Bundow D, Wilske K, and Ochs UI: Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000;75:10903-10908.
14. Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, and Atkins MB: Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997;15:1052-1062.
15. α T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000;95:3191-3198.